alexa Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.
Oncology

Oncology

Journal of Prostate Cancer

Author(s): Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF, Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF

Abstract Share this page

Abstract OBJECTIVES: To assess trends in the initial care of nonmetastatic prostate cancer, including the use of primary and adjuvant androgen deprivation therapy (ADT), using population-based treatment claims from 1991 to 1999. METHODS: We used a database linking the Surveillance, Epidemiology, and End Results (SEER) registry with Medicare claims to extract treatment information for 90,128 men aged 65 years and older, who were newly diagnosed with nonmetastatic prostate cancer. RESULTS: The use of aggressive therapy has increased among white men over time; but aggressive therapy has recently declined among African-American men. Accounting for age, grade, socioeconomic status, and comorbidity, African-American men were 26\% less likely to receive aggressive therapy than white men (odds ratio 0.74; 95\% confidence interval 0.70 to 0.79). The use of ADT has increased substantially in both the primary and the adjuvant settings. By 1999, 45.6\% of white men and 35.8\% of African-American men who selected conservative management received primary ADT; among men treated with external beam radiotherapy, the proportion receiving adjuvant ADT was 53.7\% for white men and 42.4\% for African-American men (P <0.001). CONCLUSIONS: Racial differences in the use of aggressive and conservative therapies are increasing. ADT is becoming a widely adopted component of initial treatment for localized prostate cancer. It is crucial to understand the impact of treatment patterns, including the increased use of ADT, on patient survival, morbidity, and costs of care. This article was published in Urology and referenced in Journal of Prostate Cancer

Relevant Expert PPTs

Relevant Speaker PPTs

  • Rajaram Samant
    GainmoreTM M: An oral supplementation in men with Androgenic Alopecia for reduction in hair loss & new hair growth
    PPT Version | PDF Version
  • Jack Sung
    Progenic Hair Regrowth Treatment: The Use of Platelet-Released Growth Factors for Treating Androgenetic Alopecia (AGA) by Activating Hair Follicle Stem Cells
    PPT Version | PDF Version

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords